Distinct inhibitory efficiency of siRNAs and DNAzymes to β1 integrin subunit in blocking tumor growth
Magdalena Wiktorska1, Izabela Sacewicz-Hofman, Olga Stasikowska-Kanicka
1Department of Molecular and Medical Biophysics, Medical University of Lodz, Łódź, Poland.
Abstract:
Receptors of the β1 integrin family are involved in many tumor-promoting activities. There are several approaches currently used to control integrin activity, and thus to potentially restrain tumor metastasis and angiogenesis. In this study, we compared inhibitory efficiencies of siRNA and DNAzymes against the β1 integrin subunit (DEβ1), in a mouse xenograft model. Both inhibitors were used under their most favorable conditions, in terms of concentrations, incubation time and lack of cytotoxic effects. Transfection of siRNAβ1 or DEβ1 remarkably inhibited the growth of both PC3 and HT29 colon cancer cells in vitro, and decreased their capability of initiating tumor formation in the mouse xenograft model. siRNAβ1 appeared to be slightly more efficient than DEβ1 when tested in vitro, however it was comparably less proficient in blocking the tumor growth in vivo. We conclude the DNAzyme, due to its greater resistance to degradation in extra- and intracellular compartments, to be a superior inhibitor of tumor growth in long lasting experiments in vivo when compared to siRNA, while the latter seems to be more efficient in blocking β1 expression during in vitro experiments using cell cultures.
Insights
DNAzymes and siRNA targeting β1 integrin inhibit colon cancer cell growth. DNAzymes demonstrated superior tumor growth inhibition in vivo compared to siRNA due to enhanced stability.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- β1 integrin receptors play a crucial role in tumor progression, metastasis, and angiogenesis.
- Targeting β1 integrin activity is a potential strategy to inhibit cancer growth and spread.
Purpose of the Study:
- To compare the inhibitory efficacy of small interfering RNA (siRNA) and DNAzymes against the β1 integrin subunit (DEβ1).
- To evaluate their effectiveness in inhibiting colon cancer cell growth and tumor formation in a mouse xenograft model.
Main Methods:
- In vitro studies using PC3 and HT29 colon cancer cells transfected with siRNAβ1 or DEβ1.
- In vivo evaluation in a mouse xenograft model to assess tumor growth inhibition.
- Optimization of inhibitor concentrations, incubation times, and assessment of cytotoxic effects.
Main Results:
- Both siRNAβ1 and DEβ1 significantly inhibited colon cancer cell growth in vitro and reduced tumor initiation in vivo.
- siRNAβ1 showed slightly higher efficiency in vitro, while DEβ1 was more effective in inhibiting tumor growth in vivo.
- DNAzymes exhibited greater resistance to degradation in biological compartments compared to siRNA.
Conclusions:
- DNAzymes are superior inhibitors of tumor growth in long-term in vivo experiments due to their enhanced stability.
- siRNA is more efficient in blocking β1 integrin expression during in vitro cell culture experiments.
- Both approaches show promise for targeting β1 integrin in cancer therapy.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
01:22MicroRNAs
01:22MicroRNAs
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...